That's why they announced the continued financing
Post# of 72440
Compare that to poor OCAT. OCAT was attacked by Mako -- even the "empty offices" BS was part of the Seeking Alpha attack article. OCAT took toxic financing deals, and though they had great clinical trial results, they gave up and took a bad buyout deal. Lots of shareholders lost money despite the company's scientific success.
IPIX is a whole different ball game. The company's financing is NOT toxic, and unlike OCAT, we have much more than just one drug in the pipeline.
Leo is sending a message to prospective partners, and that message is:
Pay up, or we'll find someone else whenever we feel like it.